Breaking News Instant updates and real-time market news.

AVXS

AveXis

$115.91

-3.69 (-3.09%)

, NVS

Novartis

$80.20

-0.86 (-1.06%)

08:26
04/09/18
04/09
08:26
04/09/18
08:26

Bernstein not too surprised with AveXis sale

Bernstein analyst Vincent Chen notes that Novartis (NVS) and AveXis (AVXS) announced an agreement for the former to purchase AveXis for $218 per share, a total of $8.7B. The analyst says he has long suspected he would see acquisitions in gene therapy and that AveXis could be a prime candidate, so he is not too surprised to see it go. However, the analyst acknowledges that he had not pegged Novartis as the top contender. Noting that the announcement should be a positive for others in the space, Chen reiterates an Outperform rating and $144 price target on AveXis shares.

AVXS

AveXis

$115.91

-3.69 (-3.09%)

NVS

Novartis

$80.20

-0.86 (-1.06%)

  • 23

    Apr

  • 17

    May

AVXS AveXis
$115.91

-3.69 (-3.09%)

04/09/18
MZHO
04/09/18
DOWNGRADE
MZHO
Neutral
AveXis downgraded to Neutral from Buy at Mizuho
Mizuho downgraded AveXis (AVXS) to Neutral following the acquisition by Novartis (NVS) for $218 per share in cash.
04/09/18
FBCO
04/09/18
NO CHANGE
Target $170
FBCO
Outperform
AveXis price target raised to $170 from $139 at Credit Suisse
Credit Suisse analyst Martin Auster raised his price target for AveXis to $170 from $139 to reflect his growing confidence in AVXS-101's ability to treat the broader SMA incidence population, which drives an incremental $200M in annual revenue. The analyst reiterates an Outperform rating on the stock.
02/28/18
FBCO
02/28/18
NO CHANGE
Target $139
FBCO
Outperform
AveXis price target raised to $139 from $134 at Credit Suisse
Credit Suisse analyst Martin Auster raised his price target for AveXis to $139 from $134 following a "strong" Q4 and as he believes pipeline poised to contribute. The analyst reiterates an Outperform rating on the shares.
02/28/18
WELS
02/28/18
NO CHANGE
Target $171
WELS
Outperform
AveXis price target raised to $171 from $134 at Wells Fargo
Wells Fargo analyst Jim Birchenough raised his price target for AveXis to $171 from $134 following review of Q4 progress and on the outlook for its SMA gene therapy and broader pipeline 2018. Overall, the analyst continues to expect approval of AVXS101 gene therapy for type 1 SMA by YE18, and with progress in broader development for type 2 SMA and pre-symptomatic patients with type 1, 2 and 3 SMA, he sees a potential recurring patient population of 5000 patients and $10B in market opportunity, and significant upside potential. Birchenough reiterates an Outperform rating on the shares.
NVS Novartis
$80.20

-0.86 (-1.06%)

03/21/18
WELS
03/21/18
NO CHANGE
WELS
Outperform
Amphastar court win a 'major' positive, says Wells Fargo
Wells Fargo analyst David Maris called the news of Massachusetts' District Court entering a final judgement in favor of Amphastar (AMPH) in the patent lawsuit regarding Lovenox brought by Momenta (MNTA) and Novartis' (NVS) Sandoz division a "major positive" that again demonstrates Amphastar's ability to face down larger, better-funded companies and get difficult products to market. He maintains an Outperform rating on Amphastar shares.
03/02/18
OPCO
03/02/18
INITIATION
Target $16
OPCO
Outperform
Conatus initiated with an Outperform at Oppenheimer
Oppenheimer analyst Jay Olson initiated Conatus (CNAT) with an Outperform rating and $16 price target based on his view that significant value for shareholders, physicians and patients can be unlocked by the company's "unique" approach to liver disease. In a research note to investors, Olson said he sees emricasan as well positioned to potentially demonstrate efficacy in a broad range of liver diseases, including NASH, adding that the program is viewed as "partially de-risked" through its partnership with Novartis (NVS).
02/12/18
LEER
02/12/18
NO CHANGE
Target $502
LEER
Outperform
Data from Regeneron Eylea competitors should lift some overhang, says Leerink
Leerink analyst Geoffrey Porges says that the "confusing and somewhat lackluster data" presented over the weekend for Eylea's theoretical competitors should lift some of the overhang that Regeneron's stock has suffered from over the last 6 months. Novartis' (NVS) brolucizumab pivotal trial is confusing, and the data incomplete, and the analyst has serious doubts about the drug's approvability. Secondly, the addition of Ang2 inhibition to VEGF inhibition, while theoretically intriguing, has so far been of modest benefit despite Roche's (RHHBY) posturing, he contends. Porges reiterates an Outperform rating and $502 price target on Regeneron's shares.
02/08/18
RBCM
02/08/18
INITIATION
Target $65
RBCM
Outperform
Spark Therapeutics assumed with an Outperform at RBC Capital
RBC Capital analyst Kennen MacKay assumed coverage of Spark Therapeutics (ONCE) with an Outperform rating and a price target of $65. MacKay says the FDA approval of Luxturna and "ex-Novartis (NVS) collaboration" helps to de-risk the company's earlier-stage hemophilia and inherited retinal disease assets, calling Spark Therapeutics a "trailblazer in the gene therapy space".

TODAY'S FREE FLY STORIES

SPY

SPDR S&P 500 ETF Trust

$284.67

2.87 (1.02%)

, SPX

S&P 500

$0.00

(0.00%)

13:19
08/16/18
08/16
13:19
08/16/18
13:19
Periodicals
U.S. and China to hold lower-level trade talks later in August, Reuters says »

A Chinese delegation …

SPY

SPDR S&P 500 ETF Trust

$284.67

2.87 (1.02%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:19
08/16/18
08/16
13:19
08/16/18
13:19
Hot Stocks
Breaking Hot Stocks news story  »

Rosehill Resources Inc…

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
08/16/18
08/16
13:17
08/16/18
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
08/16/18
08/16
13:16
08/16/18
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRP

TransCanada

$43.81

0.04 (0.09%)

13:13
08/16/18
08/16
13:13
08/16/18
13:13
Periodicals
Federal judge orders review of Keystone XL oil pipeline, Reuters reports »

In the latest setback for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEVA

Teva

$23.39

0.92 (4.09%)

, MYL

Mylan

$37.94

0.12 (0.32%)

13:05
08/16/18
08/16
13:05
08/16/18
13:05
Hot Stocks
Teva granted FDA approval of first generic version of EpiPen »

The U.S. Food and Drug…

TEVA

Teva

$23.39

0.92 (4.09%)

MYL

Mylan

$37.94

0.12 (0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Aug

  • 10

    Sep

  • 16

    Sep

  • 13

    Nov

GOOG

Alphabet

$1,223.00

9.35 (0.77%)

, GOOGL

Alphabet Class A

$1,239.00

6.7 (0.54%)

13:05
08/16/18
08/16
13:05
08/16/18
13:05
Periodicals
Google workers upset about company making censored engine for China, NYT says »

Hundreds of Google…

GOOG

Alphabet

$1,223.00

9.35 (0.77%)

GOOGL

Alphabet Class A

$1,239.00

6.7 (0.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 18

    Sep

  • 20

    Sep

  • 28

    Oct

13:04
08/16/18
08/16
13:04
08/16/18
13:04
Conference/Events
CFTC to hold a podcast on Agriculture Block Trade Analysis »

Dave Amato, of the U.S.…

HAFC

Hanmi Financial

$25.70

0.4 (1.58%)

13:04
08/16/18
08/16
13:04
08/16/18
13:04
Hot Stocks
Hanmi Financial announces receipt of all regulatory approvals for SWNB merger »

Hanmi Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

CLF

Cleveland-Cliffs

$9.89

0.05 (0.51%)

13:00
08/16/18
08/16
13:00
08/16/18
13:00
Options
Repeat call spreads in Cleveland Cliffs »

Repeat call spreads in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Sep

NWBI

Northwest Bancshares

$18.31

0.12 (0.66%)

13:00
08/16/18
08/16
13:00
08/16/18
13:00
Hot Stocks
Northwest Bancshares chairman William Wagner sells over 64K shares »

Northwest Bancshares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEVA

Teva

$23.47

1 (4.45%)

, MYL

Mylan

$37.84

0.02 (0.05%)

12:57
08/16/18
08/16
12:57
08/16/18
12:57
Hot Stocks
Teva rises, Mylan dips after FDA reported to approve first generic EpiPen »

Shares of Mylan (MYL)…

TEVA

Teva

$23.47

1 (4.45%)

MYL

Mylan

$37.84

0.02 (0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Aug

  • 10

    Sep

  • 16

    Sep

  • 13

    Nov

MYL

Mylan

$37.85

0.03 (0.08%)

, TEVA

Teva

$23.45

0.975 (4.34%)

12:53
08/16/18
08/16
12:53
08/16/18
12:53
Periodicals
Breaking Periodicals news story on Mylan, Teva »

FDA approves Teva generic…

MYL

Mylan

$37.85

0.03 (0.08%)

TEVA

Teva

$23.45

0.975 (4.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Aug

  • 10

    Sep

  • 16

    Sep

  • 13

    Nov

DE

Deere

$137.51

1.81 (1.33%)

12:51
08/16/18
08/16
12:51
08/16/18
12:51
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Aug

NVDA

Nvidia

$260.13

1.15 (0.44%)

, AMAT

Applied Materials

$47.71

0.22 (0.46%)

12:51
08/16/18
08/16
12:51
08/16/18
12:51
Earnings
Notable companies reporting after market close »

Notable companies…

NVDA

Nvidia

$260.13

1.15 (0.44%)

AMAT

Applied Materials

$47.71

0.22 (0.46%)

JWN

Nordstrom

$51.81

-0.05 (-0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

  • 16

    Aug

  • 16

    Aug

ADM

Archer Daniels

$50.05

0.62 (1.25%)

12:45
08/16/18
08/16
12:45
08/16/18
12:45
Recommendations
Archer Daniels analyst commentary  »

Archer Daniels price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

GOOG

Alphabet

$1,225.60

11.95 (0.98%)

, GOOGL

Alphabet Class A

$1,241.50

9.2 (0.75%)

12:38
08/16/18
08/16
12:38
08/16/18
12:38
Periodicals
Google preparing to launch display-equipped speaker for holiday season, NAR says »

Google (GOOGL) is…

GOOG

Alphabet

$1,225.60

11.95 (0.98%)

GOOGL

Alphabet Class A

$1,241.50

9.2 (0.75%)

AMZN

Amazon.com

$1,901.56

20.16 (1.07%)

BABA

Alibaba

$175.08

5.28 (3.11%)

AAPL

Apple

$213.46

3.18 (1.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

  • 22

    Aug

  • 23

    Aug

  • 10

    Sep

  • 13

    Sep

  • 18

    Sep

  • 20

    Sep

  • 28

    Oct

SPY

SPDR S&P 500 ETF Trust

$285.01

3.21 (1.14%)

, SPX

S&P 500

$0.00

(0.00%)

12:33
08/16/18
08/16
12:33
08/16/18
12:33
General news
Breaking General news story on SPDR S&P 500 ETF Trust, S&P 500 »

Mnuchin says U.S.…

SPY

SPDR S&P 500 ETF Trust

$285.01

3.21 (1.14%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$345.54

13.81 (4.16%)

12:32
08/16/18
08/16
12:32
08/16/18
12:32
Hot Stocks
Boeing to acquire Millennium Space Systems, terms not disclosed »

Boeing announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EWH

MSCI Hong Kong Index

$23.83

0.17 (0.72%)

12:30
08/16/18
08/16
12:30
08/16/18
12:30
Options
One day option play opened in iShares MSCI Hong Kong Fund »

One day option play…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
08/16/18
08/16
12:17
08/16/18
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
08/16/18
08/16
12:16
08/16/18
12:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:15
08/16/18
08/16
12:15
08/16/18
12:15
General news
Atlanta Fed's Q3 GPNow estimate was held at 4.3% »

Atlanta Fed's Q3…

CMG

Chipotle

$525.43

-0.44 (-0.08%)

12:14
08/16/18
08/16
12:14
08/16/18
12:14
Periodicals
Chipotle finds cause of foodborne illness at Ohio location, CNBC says »

Chipotle said that tests…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

TIF

Tiffany

$127.95

2.23 (1.77%)

, BABA

Alibaba

$175.17

5.37 (3.16%)

12:13
08/16/18
08/16
12:13
08/16/18
12:13
Periodicals
Tiffany to sell on Alibaba's 'Luxury Pavilion' platform on Tmall, Axios reports »

Tiffany & Co (TIF)…

TIF

Tiffany

$127.95

2.23 (1.77%)

BABA

Alibaba

$175.17

5.37 (3.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 28

    Aug

  • 10

    Sep

  • 12

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.